• linkedin
  • Increase Font
  • Sharebar

    Botulinum formulations show slight outcomes differences

    Higher success rate seen with abobotulinum, 750 U vs. onabotulinum, 200 U

    Munich, Germany—A new comparative study showed that the use of intradetrusor injections of abobotulinum toxin A (Dysport) for urinary incontinence due to neurogenic detrusor overactivity (NDO) provided results that were similar to or superior to those seen with onabotulinum toxin A (Botox), depending on the dosage of the latter.

    Urinary incontinence due to NDO in adults who have an inadequate response to or are intolerant of anticholinergic therapy has been shown to be responsive to onabotulinum toxin A. Although an increasing number of reports support the efficacy of abobotulinum toxin A for urinary incontinence, few studies have compared the two in NDO patients.

    The current retrospective case-control study was carried out by first author Benoit Peyronnet, MD, a urologist at Rennes University Hospital in Rennes, France, and his team of specialists, and was presented at the European Association of Urology annual congress in Munich, Germany. It was subsequently published online in Neurourology and Urodynamics (March 31, 2016 [Epub ahead of print]).

    The study included 211 NDO patients who were treated in three consecutives periods of time. The first time period extended from 2004 to 2006 and included the treatment of 80 patients who received onabotulinum toxin, 300 U; the second period was from 2007 to 2011 and included 78 patients who were treated with abobotulinum toxin, 750 U; and the third time period spanned the years 2011 to 2014 and studied 53 patients who received onabotulinum toxin, 200 U.

    Study authors compared urodynamic and clinical parameters among the three groups with regard to the first intradetrusor injections of three botulinum toxin formulations. The primary endpoint was the rate of success defined as the combination of urgency, urinary incontinence, and detrusor overactivity resolution.

    Next: Success rates compared


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available